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Abstract
Objectives
During premarket review, the US Food and Drug Administration may ask its Medical Device
Advisory Committee (MDAC) Panels to assess the safety and effectiveness of medical
devices being considered for approval. The objective of this study is to assess the relationship, if any, between individual votes and Panel recommendations and: (1) the composition
of Panels, specifically the expertise and demographic features of individual members; or (2)
Panel members’ propensity to speak during Panel deliberations.
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Methods
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This was a retrospective cohort study of routinely collected data from voting members of
MDAC panels convened between January 2011 to June 2016 to consider premarket
approval. Data sources were verbatim transcripts available publicly from the FDA. Number
of words spoken, directionality of votes on device approval, profession, and demographics
were collected.

Data Availability Statement: Data is publicly
available from US FDA CDRH MDAC transcripts
online. These can be accessed via the following
link: https://wayback.archive-it.org/7993/
20170404134909/https://www.fda.gov/
AdvisoryCommittees/CommitteesMeeting
Materials/MedicalDevices/Medical
DevicesAdvisoryCommittee/default.htm.
Funding: This study was supported by
Departmental Research Funds, Department of
Dermatology, Northwestern University.

Results
658,954 words spoken by 536 members during 49 meetings of 11 Panels were analyzed.
Based on multivariate analysis, biostatisticians spoke more (+373 words; P = 0.0002), and
women (-187 words; P = 0.0184) and other non-physician voting members less (-213
words; P = 0.0306), than physicians. Speaking more was associated with abstaining (P =
0.0179), and with voting against the majority (P = 0.0153). Non-physician, non-biostatistician members (P = 0.0109), and those having attended more meetings as a voting member
(P = 0.0249) were more likely to vote against approval. In bivariable analysis, unanimous
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Panels had a greater proportion of biostatisticians (mean 0.1580; 95% CI 0.1237–0.1923)
than non-unanimous Panels (0.1107; 95% CI 0.0912–0.1301; p = 0.0201).
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Panelists likely to vote against the majority include non-physician, non-biostatisticians;
experienced Panelists; and more talkative members. The increased presence of biostatisticians on Panels leads to greater voting consensus. Having a diversity of opinions on Panels,
including in sufficient numbers those members likely to dissent from majority views, may
help ensure that a diversity of opinions are aired before decision-making.

Conclusions

Introduction
The United State Food and Drug Administration (FDA) is responsible for regulating, reviewing, and approving medical drugs, devices, and cellular therapies for routine patient use. To be
approved, novel devices must be determined to be safe and effective. While FDA has clear
rules for such approvals, and copious preclinical and clinical evidence provided by companies
seeking approvals is sifted carefully by highly experienced FDA staff, FDA also engages independent experts to help decide whether specific products should be approved.
Specifically, during premarket review, FDA’s Center for Devices and Radiological Health
(CDRH) may ask its Medical Device Advisory Committee (MDAC) Panels, comprised of independent experts, to assess the safety and effectiveness of medical devices being considered for
approval. Although Panel recommendations are not binding, they greatly influence subsequent decisions by the FDA Commissioner. One study found that FDA approved nearly 90%
of original new drug and biologics license applications supported by its Advisory Committee
Panels [1].
Given the high degree of influence of Advisory Panels on approvals, it is important to
understand how such Panels operate and how they arrive at their recommendations. Beyond
the formal process of evidence review and question and answer, Panels are impacted by group
dynamics that are affected by the specific members and experts who are included, their demographic features, how much each speaks, and how they interact. While the impact of group
dynamics in FDA Panels is relatively poorly understood, further exploration of these issues
may help uncover weaknesses that can be corrected or improved. The end result may then be a
better Panel process, which is more resistant to bias, and more likely to produce good decisions. While the current FDA process for premarket approval is a gold standard worldwide,
emulated by regulatory authorities in other countries, there may be an opportunity to make it
even better.
The four principal types of participants in typical MDAC Panel meetings are the committee
members, the chair, the FDA professional staff, and the sponsor of an application. Committee
members (henceforth referred to as Panel members, or Panelists) are nominated to the MDAC
based on the relevance of their area of expertise and the extent to which they have only limited
conflicts of interest which would not preclude their serving. Most committee members have
other principal employment and are brought on as special government employees, with their
assignment to specific Panels based on their suitability to evaluate the devices or questions
under review. Members can be appointed to a particular Panel for several years, or they can be
assigned on an ad hoc basis as their expertise is required (e.g., Temporary Panel Members).
CDRH ensures that each Panel includes at least 2 voting members with clinically relevant
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expertise and one voting member who is knowledgeable about the technology of the device.
Most Panels have at least one biostatistician, who may for instance, be a faculty member at an
academic medical center. At the discretion of FDA staff, more than one biostatistician may be
assigned to a particular Panel, presumably when there is need for more complex data review,
although the reasons are not typically conveyed. Panels are comprised of physicians, non-physician experts, and biostatisticians, each recruited based on their expertise in the field.
Non-physician experts may be selected from a very large list of possible professions,
depending on the specific Panel and the particular device under consideration [2]. For the
Panels assessed in this paper, non-physician experts included epidemiologists, bioethicists,
geneticists, podiatrists, pharmacists, optometrists, electrophysiologists, engineers, other scientists, and regulatory experts.
Meetings are typically structured with presentations by FDA staff and sponsors first, followed by committee question and answer (Q&A) sessions directed to the FDA and product
sponsors, and finally an open public hearing (OPH) Q&A session with other interested parties.
After a lengthy discussion, including answering questions posed by FDA to the Panel, committee members cast formal votes on questions related to the approvability of a product, including
evaluation of post-market safety data and pre-market risk-benefit profile. The discussion and
the votes ultimately help to inform the agency’s final decisions [3, 4].
Several endogenous and exogenous factors that may be associated with Panel recommendations have recently been studied [5–7]. A study conducted by Lurie et al. found that financial ties
were weakly associated with votes for approval [6]. Another study reported that seating location–
which may determine speaking and voting order–significantly impacted voting behavior [7].
Other factors that may possibly be associated with Panel outcomes include the demographic
features and areas of expertise of Panel members, as well as the extent to which individual Panel
members speak and debate during Panel meetings. To our knowledge, the association of these
factors with the votes of individual members and overall Panel recommendations has not previously been studied. The purpose of this study was to assess the relationship, if any, between
votes and Panel recommendations and either: (1) the composition of MDAC Panels, specifically
the expertise and demographic features of individual members; or (2) Panel members’ propensity to speak during Panel deliberations. We hypothesized that certain voter characteristics may
influence voting behaviors. Specifically, we expected that those who were less likely to vote to
recommend approval and more likely to dissent from the majority vote may be more experienced (as measured by the number of Panel meetings attended); non-temporary voting members; more talkative and certain in their spoken opinions; men; and physicians.

Methods
Data sources were transcripts of US FDA CRDH MDAC Panel meetings convened between
January 2011 and June 2016 to consider premarket approval of medical devices [8]. Transcripts of Panel meetings convened for other purposes, such as review of current knowledge or
classification or reclassification of devices, were excluded. Only voting members of CDRH
MDAC participating in Panel meetings occurring in the designated period were considered in
analyses (nonvoting members such as Panel chairs, who only function as tie-breakers, and
industry representatives were excluded).
The following variables were collected for each Panel meeting: Panel name; meeting date;
names of voting members (gender was deduced from members’ name-for cases in which the
name was not commonly associated with a specific gender, we searched for identifying pronouns and photographs of the member on academic or personal websites); member profession; member opinion regarding device safety and efficacy; final member vote regarding
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device approval recommendation; number of words spoken by each voting member during
each major meeting segment (e.g., FDA question and answer [Q&A] session, sponsor Q&A
session, Panel deliberations (includes deliberations regarding official questions posed to panelists by the FDA), and open public hearing [OPH] Q&A session); and the number of meetings
attended by each member (among the meetings included in our sample- several Panel members attended multiple meetings and thus were represented several times in our sample of voting members. The variable “number of meetings attended” was coded sequentially, in
chronological order, for each Panel member). Additionally, whether or not the Panel officially
recommended device approval was determined from individual member votes.

Statistical analysis
Student’s two-tailed t-tests and Pearson chi-square tests were used to compare continuous and
categorical variables, respectively, between subgroups. Variables that had a p-value <0.10 were
included in multivariable models. A multivariable linear regression model was used to evaluate
member characteristics associated with changed in voter talkativeness (expressed as beta coefficients). Odds ratios (ORs) with 95% Wald confidence intervals (CIs) were estimated using a
logistic regression models to assess for member characteristics associated with dissenting voters (defined as voting members who voted in disagreement with the majority Panel vote
regarding final approval recommendation) and with final member vote regarding device
approval recommendation. P< 0.05 was considered statistically significant. Statistical analyses
were performed using SAS Studio software (version 3.71; SAS Institute Inc.)

Results
Panel characteristics
Forty-nine meetings of 11 Panels were included. The mean number of meetings per Panel was
4.45 (95% confidence interval [CI], 0.82–8.09). The number of voting members in attendance
ranged from 6 to 18 (mean, 10.7; 95% CI, 10.04–11.43).
The majority vote in 43 meetings (88%) was in favor of device approval. In all meetings in
which the majority was not in favor of recommending device approval, the majority of the voting members felt that there was neither reasonable assurance of device safety nor effectiveness.
Only one meeting (2.0%), the Circulatory Systems Panel meeting on October 8, 2013, resulted
in a tie vote (3 for, 3 against), necessitating a tie-breaking vote by the Panel chair, who voted in
favor of approval. This vote was excluded from analysis per our eligibility criteria.

Voting member characteristics
Characteristics of eligible voters are shown in Table 1. In 5 cases voting members were absent
during voting, and so 521 of 526 eligible votes were actually cast, 440 by men (84%): 361
(69.3%) in favor of device approval, 123 (23.6%) not in favor, and 37 (7.1%) abstentions.

Voter talkativeness
The 658,954 words spoken by voting members during the major segments of the 49 meetings
were analyzed. Most words (77%) were spoken late in the meeting during the Panel deliberations while the fewest were during OPH Q&A sessions (1%; Fig 1). Of note, voters only spoke
during OPH Q&A sessions in 10 meetings (20.4%), during all of which a majority voted for
approval. In 2 of these 10 meetings, voting members directed questions to patient speakers. In
the remainder of cases, questions were addressed to physician speakers or professional society
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Table 1. Characteristics of voting members (N = 526).
Characteristic

No. (%)

Gender
Female

116 (22)

Male

410 (78)

Member Profession
Physician

394 (75)

Biostatistician

63 (12)

Other Non-Physician Expert

69 (13)

Status
Temporary Voting Member

395 (75.1)

Voting Member

131 (24.9)

Number of Meetings Attended, Per Votera
b

Total Words Spoken , Per Voter

Mean, 2.03; 95% CI, 1.78–2.29
Mean 1252.8; 95%CI, 1187.9–1317.6

a

Number of meetings attended as a voting member between January 01, 2011-June 01, 2016

b

No. of Words Spoken During All Major Meeting Segments

https://doi.org/10.1371/journal.pone.0267134.t001

representatives, typically to request clarification of conflicts of interests or to better understand
speaker experience with device usage and adverse effects.
Bivariable analyses showed a significant association between voter talkativeness and member profession and gender (Table 2). A multivariable model of voter talkativeness (Table 2)
found being a biostatistician was independently associated with speaking significantly more
(+373 words; P = 0.0002), and any other non-physician voting member with speaking less
(-213 words; P = 0.0306), than physician members. Female gender was also independently and
significantly associated with speaking less (-187 words; P = 0.0184).

Final member vote
Bivariable analyses showed a significant relationship between final member vote (final member
vote defined as the member’s vote at the conclusion of the Panel deliberations regarding
whether or not to recommend device approval) and: (a) member profession; (b) voter certainty
(certain voters were defined as those that expressed confidence, or lack thereof, in both the
safety and effectiveness of the device; uncertain voters expressed confidence that the device
was safe, but not effective, or vice versa); (c) the number of meetings attended by the member;
and (d) voter talkativeness. The association between final member vote and voter talkativeness
was significant in all major segments of the meeting. A multinomial logistic regression model
of final member vote in this sample is shown in Table 3. Speaking more during major meeting
segments was significantly and independently associated with voting to abstain (P = 0.0179).
Compared to certain voters, the odds of uncertain voters voting to abstain or voting not in
favor of approval were nearly 6 and 12 times higher, respectively, than voting in favor of
approval (P <0.0001 for both associations). Other factors associated with voting not in favor of
recommending approval were member profession (the odds of non-physician, non-biostatistician voting members being nearly 2.5 times that of physician voters; P = 0.0109) and having
attended more meetings as a voting member (P = 0.0249).

Characteristics of uncertain voters
Analysis of uncertain voters found that 55.9% (76 of 136) voted not in favor of approval (vs
12.2% [47 of 385] of certain voters), 31.6% voted in favor of approval (vs 82.6% of certain
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Fig 1. Average number of words spoken by all voting members during major meeting segments, per meeting.
https://doi.org/10.1371/journal.pone.0267134.g001

voters), and 12.5% voted to abstain (vs 5.2% of certain voters). Of the 43 cases in which uncertain voters ultimately recommended approval, 67.4% (29 of 43) expressed confidence in the
safety of the device but were unsure of its effectiveness while 30.2% expressed confidence in
device effectiveness but were unsure of its safety. Additionally, there was one unusual case in
which a male, non-physician, temporary voting member who had attended no prior Panel
meetings abstained from commenting with regard to device safety and expressed a lack of confidence in its effectiveness, but ultimately voted to recommend device approval (which was in
agreement with the Panel majority).

Table 2. Relationship between voter characteristics and talkativenessa in the univariable and multivariable linear regression analyses.
Bivariable
Characteristic

No. (%)

β Coefficient (95% CI)

Member Status

Multivariable
P Value

β Coefficient (95% CI)

P Value

0.7124

Temporary Voting Member

395 (75)

28.2 (-121.9 to 178.2)

-

Voting Member

131 (24)

1 [Reference]

-

Member Profession
Biostatistician

63 (12)

360.0 (162.2 to 557.9)

0.0004

373.3 (176.1 to 570.6)

0.0002

Otherb

394 (75)

-254.3 (-444.6 to -64.0)

0.0089

-212.6 (-405.2 to -20.0)

0.0306

Physician

69 (13)

1 [Reference]

Female

116 (22)

-208.3 (-363.8 to -52.9)

Male

410 (78)

1 [Reference]

1 [Reference]

Member Gender

Number of Meetings Attendedc, Per 1 Meeting

-1.7 (-27.6 to 24.1)

0.0087

-187.0 (-342.3 to -31.7)

0.0184

0.8972

2

Multivariable model R (adjusted) = 0.0465; P<0.0001
Abbreviations: SD, standard deviation
a
Voter talkativeness defined as the number of words spoken by the voter during all major meeting segments (including FDA Q&A, Sponsor Q&A, open public hearing
Q&A, and Panel deliberations)
b
c

Other non-physician, non-biostatistician expert voting member (e.g. engineer, electrophysiologist, etc.)
Number of meetings attended as a voting member between January 01, 2011-June 01, 2016 that were included in our sample

https://doi.org/10.1371/journal.pone.0267134.t002
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Table 3. Bivariable and multivariable multinomial logistic regression for factors associated with voting to abstain or voting “not in favor” during the final device
approval recommendation vote.
Bivariable
Voter Characteristics

Members Who Voted to
Abstain (n = 37)

Members Who Voted to Not
Approve (n = 123)

Multivariable
Members Who Voted to
Abstain (n = 37)

Odds Ratio (95% CI)
No. of Meetings Attendeda,
Per 1 Meeting

Members Who Voted to Not
Approve (n = 123)

Odds Ratio (95% CI)

0.960 (0.815–1.131)

1.122 (1.042–1.209)b

0.932 (0.778–1.115)

1.104 (1.013–1.204)b

Entire Meetingd

1.061 (1.022–1.102)e

1.026 (0.999–1.054)

1.050 (1.008–1.093)b

1.023 (0.990–1.057)

Sponsor Q&A

0.958 (0.772–1.189)

0.988 (0.872–1.119)

FDA Q&A

1.010 (0.831–1.229)

Number of Words Spokenc:

0.966 (0.852–1.095)

Panel Deliberations + Official 1.070 (1.029–1.113)f
FDA Qs
Open Public Hearing Q&As

1.032 (1.003–1.062)b

0.881 (0.349–2.224)

1.178 (0.765–1.813)

Member Gender
Female

0.954 (0.420–2.167)

Male

0.927 (0.563–1.525)
1 [Reference]

Member Profession
Biostatistician

2.712 (1.178–6.242)b

1.741 (0.939–3.228)

2.424 (0.991–5.93)

1.568 (0.760–3.239)

Othera

0.505 (0.116–2.202)

1.943 (1.113–3.392)b

0.654 (0.146–2.928)

2.360 (1.219–4.569)b

Physician

1 [Reference]

1 [Reference]

Member Status
Temporary Voting Member

0.844 (0.402–1.774)

Voting Member

1.400 (0.851–2.303)
1 [Reference]

Certainty of Votesb
Uncertain Voter

6.286 (3.058–12.924)f

Certain Voter

11.958 (7.374–19.391)f
Reference

6.022 (2.885–12.571)f

11.979 (7.294–19.673)f
1 [Reference]

Reference group = Members who Voted to Approve (n = 361)
Abbreviations: OR, odds ratio; CI, confidence interval
a
b

Number of meetings attended as a voting member between January 01, 2011 and June 01, 2016. Meetings counted sequentially in chronological order.
p<0.05

c

Per voter, per 100 words

d

Total words spoken during major segments of the meeting (Sponsor Q&A, FDA Q&A, open public hearing Q&A, and Panel deliberations)
p<0.01

e
f

p<0.001

https://doi.org/10.1371/journal.pone.0267134.t003

Characteristics of voters not voting with the majority
Not voting with the majority (i.e., abstaining or dissenting) was significantly associated
with voter uncertainty and voter talkativeness in both bivariable and multivariable analyses, as shown in Table 4. In the multivariable model, the odds of placing a vote in disagreement with the majority was 7 times higher among uncertain voters compared to certain
voters (OR 7.098; 95%CI 4.466–11.283; P<0.0001). Voting not with majority was also independently and significantly associated with increased talkativeness during major segments
of the meeting (P = 0.0153).

Characteristics of unanimous votes
Based on bivariable analyses, unanimous Panels had a significantly greater proportion of biostatistician voting members, on average, (mean 0.1580; 95% CI 0.1237–0.1923) compared to
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Table 4. Univariable and multivariable analysis of characteristics associated with voters not voting with the majoritya.
Bivariable

Multivariable

Odds Ratio (95%CI)

P Value

Odds Ratio (95%CI)

P Value

Entire Meetingc

1.040 (1.014–1.067)

0.0028

1.038 (1.007–1.069)

0.0153

Sponsor Q&A

1.011 (0.893–1.145)

0.8612

FDA Q&A

1.027 (0.911–1.159)

0.6624

Panel Deliberations + Official FDA Qs

1.042 (1.014–1.071)

0.0032

Open Public Hearing Q&As

1.425 (0.942–2.155)

0.0932

1.069 (0.991–1.154)

0.0828

1.044 (0.957–1.138)

0.3343

Number of Words Spokenb:

Number of Meetings Attendedd (Per 1 Meeting)
Panel Status
Temporary Voting Member
Voting Member

0.4152
0.824 (0.516–1.314)

Gender
Female
Male

0.4156

1 [Reference]
0.9668
0.989 (0.599–1.634)
1 [Reference]

Member Profession

0.0821

Biostatistician

1.778 (0.982–3.220)

1.436 (0.727–2.839)

0.2976

Other Non-Physiciane

1.565 (0.872–2.808)

1.818 (0.941–3.513)

0.0751

1 [Reference]

1 [Reference]

Physician
Certainty of Votesf
Uncertain Voter
Certain Voter

7.369 (4.671–11.626)
1 [Reference]

<0.0001

7.098 (4.466–11.283)

<0.0001

1 [Reference]

Abbreviations: CI, confidence interval
a

Regarding the final vote to recommend or not recommend device approval. Voters not voting with the majority were defined as those who voted to abstain or those

who voted not in favor when the Panel majority disposition was in favor of device approval or voters who voted in favor of device approval or voted to abstain when the
Panel majority disposition was not in favor of device approval.
b

Per voter, per 100 words

c

Total words spoken during major segments of the meeting (Sponsor Q&A, FDA Q&A, open public hearing Q&A, and Panel deliberations)
d
Number of meetings attended as a voting member between January 01, 2011 and June 01, 2016. Meetings counted sequentially in chronological order.
e

Other non-physician, non-biostatistician expert (e.g. engineer, electrophysiologist, etc.)

f

Voter certainty defined as certainty with regard to confidence in the safety and effectiveness of the device. Voters who expressed confidence that the device was safe,
but not effective, or vice versa, were considered uncertain voters whereas those who expressed confidence, or lack thereof, in both the safety and effectiveness of the

device were considered certain voters
https://doi.org/10.1371/journal.pone.0267134.t004

Panels in which the final approval vote was not unanimous (mean 0.1107; 95% CI 0.0912–
0.1301; p = 0.0201).

Summary results
Voting against recommending approval at the conclusion of MDAC Panel meetings was
found to be associated with greater voter experience, uncertainty in voter opinions, and
voter profession, with those who were neither physicians nor biostatisticians more likely to
vote against approval. Abstaining during the final vote was associated with voter talkativeness. If abstaining or voting against were collectively classified as not voting with the majority, then talkative voters and uncertain voters were more likely to so vote. Biostatisticians
spoke more than physicians, and non-physicians spoke less than physicians. Women spoke
less than men.

PLOS ONE | https://doi.org/10.1371/journal.pone.0267134 June 24, 2022

8 / 12

PLOS ONE

Voting behavior during FDA panel meetings

Discussion
Some of our hypotheses were borne out, as more experienced members and more talkative
members tended to vote against approvals. Contrary to our expectations, those more certain in
their spoken opinions were less likely to abstain, vote against approval, or dissent with the
majority. Similarly, while profession impacted voting behavior, it was non-physicians rather
than physicians who were more likely to vote not to approve. Although the results for temporary voting members did not rise to significance, such members were, surprisingly, nominally
less likely to abstain and more likely to vote against approval than non-temporary members.
In interpreting the “number of works spoken” as a measure of “talkativeness,” this paper
was consistent with relevant literature. Word count is often used as a primary metric for talkativeness [9]. A separate question was whether some Panelists were garrulous but not imparting
much novel information. Interestingly, the political science literature does indicate that talkativeness, as measured by total speaking time irrespective of the semantic content, has been
shown to influence group members’ perceptions of who is contributing most to the conversation, and who is a leader within small groups [10]. Thus, Panelists who are very talkative, even
when they are repetitive and uninformative rather than eloquent or thoughtful, may be able to
sway the opinions of the Panel to some extent.
The result that speaking more was associated with abstaining or with voting against
approval was unexpected and yet interesting. A possible interpretation is that when people disagree with others, they will want to speak more. In this context, speaking more may be an
effort to delay an undesired decision or to gradually sway other Panelists in a direction that the
speaker considers more appropriate. Speaking more may also be an effort to present a range of
different arguments in support of the speaker’s position, in an effort to find some arguments
that appeal to others and may help change their minds. Finally, as the speaker continues to
explain their reasoning, they may expect to garner some other allies within the Panel who may,
in turn, help convince yet other Panelists. Since most Panel recommendation are in favor of
device approval, a talkative Panelist who is not in favor may have to be exceptionally convincing to affect their colleagues enough to alter such a recommendation.
On the other hand, women were nominally but not significantly less likely to abstain or vote
against approval than men, and they did speak significantly less than men. That women spoke
less is consistent with prior studies that show that women are less likely to participate in deliberations and decisions when they are the minority in a group, as they often are on FDA Panels [11].
Indeed, women accounted for only 22% of Panel members during the period studied. In addition, even women highly skilled at problem solving have been shown to be reluctant to engage in
complex analyses when these occur during a process that is perceived as competitive [12]. To the
extent that during a Panel meeting Panelists may be vying to speak and convince colleagues
when time for both is limited, this part of Panel deliberations may be perceived as competitive
and dissuade more women from speaking. Needless to say, receiving reduced input per Panelist
from the already smaller cohort of women on Panels is not desirable, and this problem may be
mitigated by applying current understanding of group dynamics. Specifically, majority female
Panels could be constituted and the process of being recognized to speak by the chair made less
competitive, with each Panelist given a fixed amount of time to speak and ask questions.
Biostatisticians appear to play a key role on Panels. They spoke significantly more than physicians during meetings, at least in part because biostatisticians were often asked questions by
other Panelists regarding interpretation of pivotal trial results and appropriateness of analytic
methods used. Further, meetings in which voters were able to reach unanimity with regard to
final approval recommendation were comprised of a greater proportion of biostatisticians
compared to those which were not unanimous.
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In general it appears that biostatisticians are critical for interpreting the often voluminous
and complex datasets that Panelists are asked to evaluate during the course of Panel meetings.
FDA and the corporate sponsors do separately present detailed evidence regarding safety and
effectiveness for the Panelists’ consideration, but many clinically adept Panelists may still
struggle to understand the details of specific analyses, to what extent the data are definitive,
and whether study design and data analysis were adequate. As members of the Panel itself, biostatisticians are perceived as relatively unbiased by other Panel members, and biostatisticians
are also deemed to be expert at judging the integrity of the process whereby quantitative data
was collected and assessed. To the extent that biostatisticians can reassure other Panelists that
the data collection was precise, data analysis was performed correctly, and differences between
experimental and control groups were valid, then the Panelists can be confident that their
judgments regarding the suitability of a drug or device for approval are built on a solid foundation. This increased certainty, in turn, allows Panelists to be willing to come to agreement and
make collective decisions, as versus in the situation where a lack of confidence makes some
Panelists reluctant to commit. When disagreements occur among Panelists who are clinicians,
biostatisticians, by virtue of being perceived as agnostic about technical medical issues as well
as inherently dispassionate and data-driven, may be able to cool overheated tempers and
return the Panelists to the more neutral ground of checking the numbers and effect size. Nonclinician Panel members, such as those expert on the underlying technology of a device, may
be less able to follow the nuance of discussion of clinical issues but may feel more comfortable
with the statistical analyses, as explained by the biostatistician. In sum, having more biostatisticians on the Panel may improve, in a more uniform manner, the understanding of study
design and data interpretation among voting members leading to greater voter consensus.
Non-physician, non-biostatistician voters, on the other hand, appear to be unfamiliar with,
or unwilling to participate in, the consensus process that is integral to a Panel meeting. Possibly
their frame of reference is different than that of physician and biostatistician voters, and they
may be expecting a higher level of scientific evidence than is available in human clinical trials.
Almost a quarter of voters were so-called uncertain voters, who asserted either that the
device under review was effective but not safe, or safe but not effective. While a majority of
uncertain voters cast final votes against approval, a substantial minority voted to approve.
When they did cast a vote in favor of approval, uncertain voters appeared to place more weight
on device safety than effectiveness, presumably because they felt uncertain effectiveness was
less potentially harmful to patients than uncertain safety. The odd behavior of uncertain voters
may be ascribed to a high level of doubt about the right course of action.
Although only 69% of individual votes were in favor or recommending device approval,
88% of Panels ultimately endorsed device approval. This appears related to the voting mechanism, whereby one or a few voting member’s strong opposition cannot override a majority
vote in favor of approval.
The words spoken during the Panel deliberation session immediately preceding the final
approval vote accounted for, on average, over three-quarters of the total words spoken by voting members during the meeting. This suggests that voting members typically wait to express
their opinions and arrive at judgments, doing more listening than talking during earlier meeting segments.
That voting members seldom ask questions during OPH Q&A sessions, and if they did
directed these to physician speakers or society representatives, not patients, is consistent with a
recent survey study of MDAC Panel members. Survey respondents reported that OPH sessions
were generally not influential in their recommendation decision, but they did find comments
from society representatives to be helpful (M. Alam, A. Maisel, B. Cressey, et al.; unpublished
data; December 2019).
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Experienced voters may be more willing to vote against approval because, by attending
more meetings, they have gained experience reviewing and evaluating evidence that provides
them increased confidence in their assessments. Conversely, less experienced members may be
less confident in their ability to properly sift the data and hence reluctant to vote against a
majority. It appears that there is a significant learning curve for Panelists, with more experienced Panelists better able to perform the critical function of illuminating shortcomings in
devices.
While we were limited by the number of Panel meetings that occurred in the time period of
interest, the decision to restrict the inclusion criteria to a relatively short, recent time period was
intentional. Since the rules governing functioning of FDAC Panel meetings has evolved over
time (e.g. types of devices being approved, conflict of interest rules, gender balance, etc.), a longer time window would have resulted in internal validity issues, and been less generalizable to
current Panels. Future studies may assess whether the current findings are generalizable to different contexts, such as FDA drug (CDRH) Panels convened for premarket approval. Future
studies may also include content analysis of the words being spoken during Panel meetings.
Overall, this analysis is reassuring in that it shows that MDAC Panel members feel comfortable disagreeing with the Panel majority when they are concerned about some aspect of the
device under review. In general, Panel members appear to weigh safety more than effectiveness,
as is reasonable given the potential harm that can occur from approving unsafe products. While
most members vote in favor of approval, those with greater Panel experience, uncertainty in
their opinions, and professions other than medicine or biostatistics are more likely to vote
against approval, and their inclusion is likely useful for ensuring Panels have the opportunity to
hear and consider opposing views. Biostatisticians play an important role on Panels, helping to
inform voters regarding technical aspects of data analysis, and bringing them to consensus.
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